Clinical Trial Signal Monitor $49
Pricing

Follow the trials that matter. Pay when you need history.

Free public search and FDA cards. Monitor follows 25 trials on your desk. Pro follows 50, exports CSV, and pulls PubMed, openFDA, and EU CTIS for those trials. No email.

Free
$0

Search public registries. See live trial movement, FDA safety alerts, and openFDA recalls.

  • ✓Search ClinicalTrials.gov (top 5)
  • ✓Live FDA MedWatch alerts
  • ✓Latest openFDA recalls
  • ·No saved trials
  • ·No exports
  • ·No AI brief
Pro
$199/month
Or $1,990/year · 2 months included

Same desk. 50 trials. CSV of your list. PubMed, openFDA, and EU CTIS for the trials you follow.

  • ✓Follow 50 trials
  • ✓Stored values, then Changed
  • ✓CSV of your desk
  • ✓PubMed records for each followed trial
  • ✓openFDA recalls for the sponsor
  • ✓EU CTIS lookup
  • ✓Links to WHO ICTRP and ISRCTN search

Subscription auto-renews monthly at $199 until cancelled. Cancel any time. Agree to Terms.

FreeMonitor $49Pro $199
Public CT.gov + FDA cardsYesYesYes
Follow trials on your deskNo2550
Stored values, then ChangedNoYesYes
CSV of your deskNoNoYes
PubMed, openFDA, EU CTISNoNoYes

Monitor is $49/month. Subscribe any time. Cancel any time. Annual billing includes 2 months. By subscribing you agree to our Terms and Privacy Policy.

Every signal is source-backed

Source · source URL · source published timestamp · ingested timestamp · previous value · new value · normalized signal · AI-assisted interpretation · caveat. Export PDF or CSV for any record. This is the same evidence that backs every card you see across Clinical Trial Signal.

Evidence record Example evidence record Notable
Trial primary-completion change · Phase 3 GLP-1 obesity (illustrative)
SourceClinicalTrials.gov registry
Source URLDeep link to the live NCT record (shown on real signals)
Source published2026-05-30T00:00:00Z
Ingested2026-05-30T04:12:48Z
Previous valuePrimaryCompletion = 2026-12-15
New valuePrimaryCompletion = 2027-06-15
Normalized signaltrial.primary_completion_shift · delta = +6 months · severity = notable
AI-assisted interpretationA 6-month shift on a lead Phase 3 read-out moves the sponsor's regulatory submission window out of 2026, with downstream implications for competing-program timing and BD windows.
Registry date moves do not establish cause. The sponsor has not publicly disclosed a reason in the registry record.